GlassScriptPhysician profile
Paula Amaro
NPI 1518589852
$681.14
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.78 · 2022: $337 · 2023: $50.47 · 2024: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $236.44 | 2022-2024 | |
| Teleflex LLC | $117.50 | 2024 | Urolift |
| Mayne Pharma Commercial LLC | $79.22 | 2022 | |
| Lilly USA, LLC | $45.70 | 2021-2024 | Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $33.95 | 2022 | |
| Glaxosmithkline, LLC. | $30.81 | 2022-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $20.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.84 | 2024 | Austedo Xr |
| Pfizer INC. | $18.24 | 2024 | |
| Bausch Health US, LLC | $18.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.84 | 2021 | |
| Amarin Pharma, INC. | $14.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Amaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.